1-5 of 5
Matthew Foster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Personalized and Optimized Low-Dose and Intensive Chemotherapy Treatments for Patients with Acute Myeloid Leukemia (AML)

Ana Luz Quiroga-Campano, PhD MSc, BSc, Louise Enfield, Matthew Foster, BS, Margaritis Kostoglou, PhD, Michael Georgiadis, PhD, Athanasios Mantalaris, PhD, Nicki Panoskaltsis, MD PhD FRCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 3500.
https://doi.org/10.1182/blood-2018-99-119258
Published: 2018
Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1349.
https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349
Published: 2017
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017
Journal Articles

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

Tara L. Lin, MD, Geoffrey L. Uy, MD, Matthew J. Wieduwilt, Laura F. Newell, MD, Robert K. Stuart, MD, Bruno C Medeiros, MD, Gary J. Schiller, Eric Rubenstein, MD, Wendy Stock, MD, Erica D. Warlick, MD, Matthew Foster, Dale L. Bixby, Nikolai A. Podoltsev, MD PhD, Qi An, Stefan Faderl, Arthur C. Louie, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1698.
https://doi.org/10.1182/blood.V130.Suppl_1.1698.1698
Published: 2017